Cooley advised Geron, while Latham & Watkins represented the underwriters in the offering. Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, has announced the pricing...
Geron Corporation’s $198 Million Upsized Public Offering
Terns Pharmaceuticals’ $86 Million Common Stock Offering
Latham & Watkins LLP represented Terns Pharmaceuticals in the offering and Davis Polk advised the underwriters involved. Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company...
Vaxcyte’s $690 Million Public Offering
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...
Orbital Therapeutics’ Partnership With Beam Therapeutics
Latham & Watkins advised Orbital Therapeutics on the deal. Orbital Therapeutics, which aims to enhance global health by unleashing the full potential of RNA medicine, announced...
Alpine Immune Sciences’ $100 Million Shares Offering
Wilson Sonsini Goodrich & Rosati represented Alpine, while Latham & Watkins represented to underwriters in the offering. Alpine Immune Sciences, Inc. (Nasdaq: ALPN) has announced the pricing...
UNITY Biotechnology’s $45 Million Shares Offering
Latham & Watkins represented UNITY Biotechnology in the transaction. UNITY Biotechnology, Inc. (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, has...
Terns Pharmaceuticals’ $65 Million Common Stock Offering
Latham & Watkins represented Terns Pharmaceuticals in the offering, while Davis Polk & Wardwell represented the underwriters. Terns Pharmaceuticals, Inc. (Nasdaq: TERN) has agreed to sell, by...
Mirum Pharmaceuticals’ $80 Million Common Stock Offering
Cooley represented Mirum Pharmaceuticals, while Latham & Watkins represented the underwriters in the offering. Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition,...
Athenex, Inc.’s $30 Million Public Offering
Harter Secrest & Emery LLP assisted Athenex, Inc., while the underwriter was represented by Latham & Watkins LLP. Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company...
Arcutis Biotherapeutics’ $150 Million Shares Offering
Latham & Watkins advised Arcutis Biotherapeutics, Inc. in the offering, while Cooley represented the underwriters. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced the pricing of its underwritten...
Chinook Therapeutics’ $105 Million Public Offering
Latham & Watkins represented the underwriters in the offering. Chinook Therapeutics, Inc. (Nasdaq: KDNY) has announced the pricing of its underwritten public offering of 6,428,572 shares...
Twist Bioscience’s $250 Million Common Stock Offering
Orrick, Herrington & Sutcliffe advised Twist Bioscience, while Latham & Watkins represented the underwriters in the offering. Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers...